Dystroglycanopathy muscles lacking functional glycosylation of alpha-dystroglycan retain regeneration capacity

Neuromuscular Disorders

Volumn 25, Issue 6, 2015, Pages 474-484

  Awano, Hiroyuki ^a   Blaeser, Anthony ^a   Wu, Bo ^a   Lu, Pei ^a   Keramaris Vrantsis, Elizabeth ^a   Lu, Qi ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Dystroglycanopathy; Fukutin related protein; Muscle regeneration; Muscular dystrophy

Indexed keywords

ALPHA DYSTROGLYCAN; MYOSIN HEAVY CHAIN; PROTEIN P16; DYSTROGLYCAN; FKRP PROTEIN, MOUSE; LARGE PROTEIN, MOUSE; N ACETYLGLUCOSAMINYLTRANSFERASE; NOTEXIN; PROTEIN; SNAKE VENOM; TRANSCRIPTION FACTOR PAX7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DYSTROGLYCANOPATHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MUTANT; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SKELETAL MUSCLE SATELLITE CELL; WILD TYPE; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; GLYCOSYLATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; SKELETAL MUSCLE CELL; SKELETAL MYOBLAST;

ANIMALS; CELLS, CULTURED; DYSTROGLYCANS; ELAPID VENOMS; GLYCOSYLATION; HUMANS; MICE; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHIES; MYOBLASTS, SKELETAL; N-ACETYLGLUCOSAMINYLTRANSFERASES; PAX7 TRANSCRIPTION FACTOR; PROTEINS; REGENERATION;

EID: 84929652820     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.03.004     Document Type: Article

References (53)

1. Martin P.T. Congenital muscular dystrophies involving the O-mannose pathway. Curr Mol Med 2007, 7:417-425.
2. Manzini M.C., Tambunan D.E., Hill R.S., et al. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am J Hum Genet 2012, 91:541-547.
3. Vuillaumier-Barrot S., Bouchet-Seraphin C., Chelbi M., et al. Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am J Hum Genet 2012, 91:1135-1143.
4. Willer T., Lee H., Lommel M., et al. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet 2012, 44:575-580.
5. Buysse K., Riemersma M., Powell G., et al. Missense mutations in beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum Mol Genet 2013, 22:1746-1754.
6. Jae L.T., Raaben M., Riemersma M., et al. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 2013, 340:479-483.
7. Stevens E., Carss K.J., Cirak S., et al. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of alpha-dystroglycan. Am J Hum Genet 2013, 92:354-365.
8. Longman C., Brockington M., Torelli S., et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003, 12:2853-2861.
9. van Reeuwijk J., Janssen M., van den Elzen C., et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 2005, 42:907-912.
10. Beltran-Valero de Bernabe D., Currier S., Steinbrecher A., et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002, 71:1033-1043.
11. Yoshida A., Kobayashi K., Manya H., et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001, 1:717-724.
12. Kobayashi K., Nakahori Y., Miyake M., et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394:388-392.
13. Brockington M., Yuva Y., Prandini P., et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001, 10:2851-2859.
14. Brockington M., Blake D.J., Prandini P., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001, 69:1198-1209.
15. Manya H., Chiba A., Yoshida A., et al. Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci U S A 2004, 101:500-505.
16. Yoshida-Moriguchi T., Willer T., Anderson M.E., et al. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 2013, 341:896-899.
17. Inamori K., Hara Y., Willer T., et al. Xylosyl- and glucuronyltransferase functions of LARGE in alpha-dystroglycan modification are conserved in LARGE2. Glycobiology 2013, 23:295-302.
18. Kuga A., Kanagawa M., Sudo A., et al. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of alpha-dystroglycan. J Biol Chem 2012, 287:9560-9567.
19. Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., Campbell K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990, 345:315-319.
20. Yoshida M., Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem 1990, 108:748-752.
21. Ervasti J.M., Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66:1121-1131.
22. Ervasti J.M., Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993, 122:809-823.
23. Kanagawa M., Toda T. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 2006, 51:915-926.
24. Campanelli J.T., Roberds S.L., Campbell K.P., Scheller R.H. A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell 1994, 77:663-674.
25. Gee S.H., Montanaro F., Lindenbaum M.H., Carbonetto S. Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell 1994, 77:675-686.
26. Talts J.F., Andac Z., Gohring W., Brancaccio A., Timpl R. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J 1999, 18:863-870.
27. Sugita S., Saito F., Tang J., Satz J., Campbell K., Sudhof T.C. A stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol 2001, 154:435-445.
28. Montanaro F., Lindenbaum M., Carbonetto S. alpha-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability. J Cell Biol 1999, 145:1325-1340.
29. Brown S.C., Fassati A., Popplewell L., et al. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction. J Cell Sci 1999, 112(Pt 2):209-216.
30. Sato S., Omori Y., Katoh K., et al. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci 2008, 11:923-931.
31. Henry M.D., Campbell K.P. A role for dystroglycan in basement membrane assembly. Cell 1998, 95:859-870.
32. Williamson R.A., Henry M.D., Daniels K.J., et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 1997, 6:831-841.
33. Cohn R.D., Henry M.D., Michele D.E., et al. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 2002, 110:639-648.
34. Ross J., Benn A., Jonuschies J., et al. Defects in glycosylation impair satellite stem cell function and niche composition in the muscles of the dystrophic Large(myd) mouse. Stem Cells 2012, 30:2330-2341.
35. Blaeser A., Keramaris E., Chan Y.M., et al. Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes. Hum Genet 2013, 132:923-934.
36. Chan Y.M., Keramaris-Vrantsis E., Lidov H.G., et al. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum Mol Genet 2010, 19:3995-4006.
37. Chiu Y.H., Hornsey M.A., Klinge L., et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009, 18:1976-1989.
38. Marques M.J., Ferretti R., Vomero V.U., Minatel E., Neto H.S. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve 2007, 35:349-353.
39. Anderson J.E. Dystrophic changes in mdx muscle regenerating from denervation and devascularization. Muscle Nerve 1991, 14:268-279.
40. Moschella M.C., Ontell M. Transient and chronic neonatal denervation of murine muscle: a procedure to modify the phenotypic expression of muscular dystrophy. J Neurosci 1987, 7:2145-2152.
41. Toydemir R.M., Rutherford A., Whitby F.G., Jorde L.B., Carey J.C., Bamshad M.J. Mutations in embryonic myosin heavy chain (MYH3) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. Nat Genet 2006, 38:561-565.
42. McGeachie J.K., Grounds M.D., Partridge T.A., Morgan J.E. Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci 1993, 119:169-179.
43. Karpati G., Carpenter S., Prescott S. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 1988, 11:795-803.
44. Holzfeind P.J., Grewal P.K., Reitsamer H.A., et al. Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle - eye - brain disorders. Hum Mol Genet 2002, 11:2673-2687.
45. Preston S.A., Davis C.E., Harris J.B. The assessment of muscle fibre loss after the injection of the venom of Notechis scutatus (Australian tiger snake). Toxicon 1990, 28:201-214.
46. Seale P., Sabourin L.A., Girgis-Gabardo A., Mansouri A., Gruss P., Rudnicki M.A. Pax7 is required for the specification of myogenic satellite cells. Cell 2000, 102:777-786.
47. Lepper C., Partridge T.A., Fan C.M. An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. Development 2011, 138:3639-3646.
48. Kottlors M., Kirschner J. Elevated satellite cell number in Duchenne muscular dystrophy. Cell Tissue Res 2010, 340:541-548.
49. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275.
50. Krishnamurthy J., Ramsey M.R., Ligon K.L., et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457.
51. Molofsky A.V., Slutsky S.G., Joseph N.M., et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006, 443:448-452.
52. Sousa-Victor P., Gutarra S., Garcia-Prat L., et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 2014, 506:316-321.
53. Kanagawa M., Yu C.C., Ito C., et al. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Hum Mol Genet 2013, 22(15):3003-3015.